Verastem Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Verastem de 42.5% y 38% respectivamente, mientras que el BPA crecerá en un 50.1% al año.
Información clave
42.5%
Tasa de crecimiento de los beneficios
50.14%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 28.7% |
| Tasa de crecimiento de los ingresos | 38.0% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 01 Sep 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
VSTM: Upcoming KRAS Data And Pancreatic Trial Results Will Drive Repricing
Verastem's analyst price target has moved from $8.85 to $11.00, reflecting updated models after recent Q2 results and supporting research that still points to generally positive views on the stock despite reduced targets across several firms. Analyst Commentary Recent Street research on Verastem shows that many analysts still maintain positive ratings, even as they reduce their price targets following Q2 results and updated models.
VSTM: Upcoming KRAS G12D Data Readout Will Drive The Next Repricing
Analysts have trimmed their average price target on Verastem from about $16.13 to roughly $14.75, citing updated Q2 models that reflect refined revenue growth and profitability assumptions, while largely maintaining constructive views on the company. Analyst Commentary Recent research updates on Verastem reflect a mix of optimism around execution and product launches, alongside more cautious views on competition and risk.
VSTM: TARGET-D Trials Will Shape Future Upside In Crowded KRAS Space
Verastem's analyst fair value estimate has moved from $20.00 to $18.00 as analysts recalibrate their models and lower price targets in light of recent Q1 and Q2 updates and a more crowded competitive field. Analyst Commentary Recent Street research on Verastem shows a cluster of lower price targets following Q1 and Q2 updates, yet many bullish analysts are maintaining positive views on the stock.VSTM: Future KRAS Data And Pancreatic Trial Progress Will Drive Repricing
The Verastem analyst price target has been revised lower, with a fair value estimate moving from about $14.00 to about $8.85 as analysts factor in a less favorable long thesis in a more crowded competitive space and updated post-earnings models. Analyst Commentary on Verastem Recent Street research on Verastem reflects a more cautious tone, with several bearish analysts trimming their fair value assumptions and reassessing the long thesis after recent earnings and competitive updates.Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results
It's been a sad week for Verastem, Inc. ( NASDAQ:VSTM ), who've watched their investment drop 18% to US$4.89 in the...RAS And MAPK Cancer Pipeline Will Drive Long Term Upside Potential
Catalysts About Verastem Verastem is an oncology company focused on therapies for RAS and MAPK pathway driven cancers, including KRAS mutated recurrent low grade serous ovarian cancer. What are the underlying business or industry changes driving this perspective?Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump
Verastem, Inc. ( NASDAQ:VSTM ) shareholders won't be pleased to see that the share price has had a very rough month...Verastem: The Market Is Ignoring The Progress
Summary FDA approval of AVMAPKI FAKZYNJA CO-PACK marks a transformative milestone, positioning Verastem as a commercial-stage leader in KRAS-mutant LGSOC treatment. Verastem's strong cash position and promising pipeline, including VS-7375 for KRAS G12D, offer significant upside with multiple near-term catalysts ahead. Risks include slow commercial uptake, pipeline uncertainty, and potential future dilution, but current valuation under $5 presents an attractive entry point. I maintain a 3/5 conviction, plan to add to my position below $5.75, and aim to hold long-term as VSTM targets KRAS-driven cancers. Read the full article on Seeking AlphaVerastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade
Summary Verastem's stock plummeted after updates showed reduced efficacy in cancer treatment trials, causing a reassessment of strategy. Updated clinical trial results show a significant drop in response rates, suggesting less robust efficacy than earlier believed. Financially, Verastem has only a year of cash runway and faces significant dilution risks to extend it. Downgrade the recommendation to 'hold' due to increased risks and market volatility associated with microcap stocks. Read the full article on Seeking AlphaPrevisiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 262 | -112 | -97 | -88 | 7 |
| 12/31/2027 | 181 | -157 | -150 | -145 | 8 |
| 12/31/2026 | 116 | -166 | -166 | -162 | 9 |
| 6/30/2026 | 88 | -203 | -172 | -162 | N/A |
| 3/31/2026 | 50 | -194 | -161 | -151 | N/A |
| 12/31/2025 | 31 | -209 | -147 | -138 | N/A |
| 9/30/2025 | 13 | -241 | -141 | -133 | N/A |
| 6/30/2025 | 2 | -167 | -120 | -120 | N/A |
| 3/31/2025 | 10 | -149 | -115 | -115 | N/A |
| 12/31/2024 | 10 | -131 | -105 | -105 | N/A |
| 9/30/2024 | 10 | -93 | -109 | -109 | N/A |
| 6/30/2024 | 10 | -89 | -102 | -102 | N/A |
| 3/31/2024 | N/A | -106 | -95 | -94 | N/A |
| 12/31/2023 | N/A | -87 | -86 | -86 | N/A |
| 9/30/2023 | N/A | -77 | -73 | -73 | N/A |
| 6/30/2023 | N/A | -75 | -72 | -72 | N/A |
| 3/31/2023 | N/A | -73 | -65 | -65 | N/A |
| 12/31/2022 | 3 | -74 | -64 | -64 | N/A |
| 9/30/2022 | 3 | -73 | -57 | -57 | N/A |
| 6/30/2022 | 3 | -78 | -53 | -53 | N/A |
| 3/31/2022 | 4 | -73 | -53 | -53 | N/A |
| 12/31/2021 | 2 | -71 | -54 | -54 | N/A |
| 9/30/2021 | 2 | -75 | -65 | -65 | N/A |
| 6/30/2021 | 81 | -39 | -10 | -10 | N/A |
| 3/31/2021 | 84 | -45 | -19 | -19 | N/A |
| 12/31/2020 | 89 | -68 | -34 | -34 | N/A |
| 9/30/2020 | 92 | -87 | -49 | -49 | N/A |
| 6/30/2020 | 22 | -130 | -122 | -122 | N/A |
| 3/31/2020 | 21 | -149 | N/A | -134 | N/A |
| 12/31/2019 | 17 | -149 | N/A | -139 | N/A |
| 9/30/2019 | 15 | -122 | N/A | -120 | N/A |
| 6/30/2019 | 22 | -113 | N/A | -115 | N/A |
| 3/31/2019 | 28 | -89 | N/A | -91 | N/A |
| 12/31/2018 | 27 | -72 | N/A | -75 | N/A |
| 9/30/2018 | 26 | -79 | N/A | -76 | N/A |
| 6/30/2018 | 10 | -81 | N/A | -65 | N/A |
| 3/31/2018 | N/A | -76 | N/A | -69 | N/A |
| 12/31/2017 | N/A | -68 | N/A | -57 | N/A |
| 9/30/2017 | N/A | -61 | N/A | -43 | N/A |
| 6/30/2017 | N/A | -46 | N/A | -37 | N/A |
| 3/31/2017 | N/A | -41 | N/A | -29 | N/A |
| 12/31/2016 | N/A | -36 | N/A | -29 | N/A |
| 9/30/2016 | N/A | -37 | N/A | -34 | N/A |
| 6/30/2016 | N/A | -44 | N/A | -39 | N/A |
| 3/31/2016 | N/A | -51 | N/A | -45 | N/A |
| 12/31/2015 | N/A | -58 | N/A | -46 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que VSTM siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que VSTM siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que VSTM siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (38% al año) de VSTM crezcan más rápidamente que los del mercado US (13.5% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (38% al año) de VSTM crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de VSTM se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/10 02:34 |
| Precio de las acciones al final del día | 2026/09/10 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Verastem, Inc. está cubierta por 30 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Matthew Cross | Alliance Global Partners |
| James Molloy | Alliance Global Partners |
| Matthew Venezia | Alliance Global Partners |